Fed. Circ. Says Amgen's Repatha Patents Are Too Expansive
By Dani Kass (February 11, 2021, 10:27 PM EST) -- A Delaware federal judge rightly found that claims of two Amgen patents covering its cholesterol medication Repatha are too broad to be enabled, the Federal Circuit said Thursday in a win for Sanofi and Regeneron.
A three-judge panel concluded it would have taken undue experimentation to figure out the bounds of the claims in Amgen's patents, making it unable to meet enablement requirements under Section 112 of the Patent Act.
"The functional limitations here are broad, the disclosed examples and guidance are narrow, and no reasonable jury could conclude under these facts that anything but 'substantial time and effort' would be...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!